Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, Maastricht, The Netherlands.
Department of Clinical Genetics, Maastricht University Medical Centre, Maastricht, The Netherlands.
Eur J Heart Fail. 2021 Jun;23(6):933-944. doi: 10.1002/ejhf.2201. Epub 2021 Jun 24.
To determine the prognostic value of multilevel assessment of fibrosis in dilated cardiomyopathy (DCM) patients.
We quantified fibrosis in 209 DCM patients at three levels: (i) non-invasive late gadolinium enhancement (LGE) at cardiac magnetic resonance (CMR); (ii) blood biomarkers [amino-terminal propeptide of procollagen type III (PIIINP) and carboxy-terminal propeptide of procollagen type I (PICP)], (iii) invasive endomyocardial biopsy (EMB) (collagen volume fraction, CVF). Both LGE and elevated blood PICP levels, but neither PIIINP nor CVF predicted a worse outcome defined as death, heart transplantation, heart failure hospitalization, or life-threatening arrhythmias, after adjusting for known clinical predictors [adjusted hazard ratios: LGE 3.54, 95% confidence interval (CI) 1.90-6.60; P < 0.001 and PICP 1.02, 95% CI 1.01-1.03; P = 0.001]. The combination of LGE and PICP provided the highest prognostic benefit in prediction (likelihood ratio test P = 0.007) and reclassification (net reclassification index: 0.28, P = 0.02; and integrated discrimination improvement index: 0.139, P = 0.01) when added to the clinical prediction model. Moreover, patients with a combination of LGE and elevated PICP (LGE+/PICP+) had the worst prognosis (log-rank P < 0.001). RNA-sequencing and gene enrichment analysis of EMB showed an increased expression of pro-fibrotic and pro-inflammatory pathways in patients with high levels of fibrosis (LGE+/PICP+) compared to patients with low levels of fibrosis (LGE-/PICP-). This would suggest the validity of myocardial fibrosis detection by LGE and PICP, as the subsequent generated fibrotic risk profiles are associated with distinct cardiac transcriptomic profiles.
The combination of myocardial fibrosis at CMR and circulating PICP levels provides additive prognostic value accompanied by a pro-fibrotic and pro-inflammatory transcriptomic profile in DCM patients with LGE and elevated PICP.
确定扩张型心肌病(DCM)患者中纤维化的多层次评估的预后价值。
我们在 209 例 DCM 患者中进行了纤维化的三个水平的定量评估:(i)心脏磁共振(CMR)中的非侵入性晚期钆增强(LGE);(ii)血液生物标志物[III 型前胶原氨基端肽(PIIINP)和 I 型前胶原羧基端肽(PICP)];(iii)心内膜心肌活检(EMB)(胶原容积分数,CVF)。在调整已知临床预测因素后,LGE 和升高的血液 PICP 水平,但既不是 PIIINP 也不是 CVF 预测了更差的结局,定义为死亡、心脏移植、心力衰竭住院或危及生命的心律失常,(调整后的危险比:LGE 3.54,95%置信区间(CI)1.90-6.60;P<0.001 和 PICP 1.02,95%CI 1.01-1.03;P=0.001)。LGE 和 PICP 的组合在预测(似然比检验 P=0.007)和重新分类(净重新分类指数:0.28,P=0.02;和综合判别改善指数:0.139,P=0.01)方面提供了最高的预后获益,当添加到临床预测模型中时。此外,LGE 和升高的 PICP (LGE+/PICP+)的患者具有最差的预后(对数秩 P<0.001)。EMB 的 RNA 测序和基因富集分析显示,与纤维化水平较低的患者(LGE-/PICP-)相比,纤维化水平较高的患者(LGE+/PICP+)中促纤维化和促炎途径的表达增加。这表明 LGE 和 PICP 检测心肌纤维化的有效性,因为随后产生的纤维化风险谱与不同的心脏转录组谱相关。
CMR 中的心肌纤维化与循环 PICP 水平的组合在 LGE 和升高的 PICP 的 DCM 患者中提供了附加的预后价值,并伴有促纤维化和促炎的转录组特征。